Last reviewed: June 30, 2026

Last updated: June 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide medications like Ozempic activate GLP-1 receptors in the brain to reduce hunger and slow stomach emptying, leading to an average weight loss of 5–22% of body weight in clinical trials. However, not every person responds identically to the same medication at the same dose, which is why PlexusDx uses genetic testing and personalized protocols to match you with the right therapy.

Why Semaglutide Results Vary Among Patients

Clinical studies show that semaglutide produces weight loss in the majority of participants, but the magnitude of loss ranges dramatically from person to person. Some patients lose 10% of their body weight, while others achieve 25% or more over the same treatment period. This variation stems from differences in GLP-1 receptor sensitivity, baseline metabolism, insulin resistance, appetite regulation genetics, and adherence to diet and exercise modifications.

Your genetic makeup influences how strongly your GLP-1 receptors respond to medication. Variants in the GLP1R gene (such as rs6923761) and other metabolic genes like FTO and MC4R affect how semaglutide works in your body. Two patients taking identical doses may experience completely different hunger suppression and weight loss rates because their peptide pathways function differently. PlexusDx Precision Peptide Genetic Test identifies these variants to predict your likelihood of strong versus modest response.

Lifestyle factors—including calorie intake, exercise frequency, sleep quality, and stress levels—determine whether semaglutide reaches its full potential. The medication is a tool that suppresses appetite and improves satiety, but it cannot override consistently high calorie consumption. Patients who combine semaglutide with balanced nutrition and regular activity see the most dramatic weight loss, while those who maintain poor eating habits may see minimal results despite taking the medication.

Clinical Evidence on Semaglutide Weight Loss Rates

The STEP trials (Semaglutide Treatment Effect in People with Obesity) followed patients for 68 weeks and showed average weight loss of 9.2–15.3% depending on dose and population. Patients receiving the highest dose (2.4 mg weekly) lost approximately 15% of baseline body weight, compared to 2.6% in the placebo group. However, these averages mask individual outcomes: some participants lost 30% while others lost less than 5%, demonstrating that average results do not predict personal outcomes.

Long-term data from the SUSTAIN trials (in people with type 2 diabetes) and real-world studies confirm that sustained weight loss requires continued medication use. When patients stop semaglutide, weight typically returns within months, indicating the medication works as an ongoing treatment rather than a permanent solution. PlexusDx addresses this by offering ongoing support and dose optimization to maintain results.

How PlexusDx Personalizes Your Semaglutide Therapy

PlexusDx moves beyond one-size-fits-all dosing by analyzing your genetic profile through the Precision Peptide Genetic Test (available as a $99 add-on after your first month). The test identifies key variants in GLP1R, GIPR, FTO, and MC4R genes—plus insights across 14 metabolic pathways and 49 peptides—to predict your therapy response and guide dose escalation timing. This genetic insight helps determine whether you'll respond best to semaglutide, tirzepatide, or a dual-compound protocol.

PlexusDx Compounded Semaglutide Injection starts at $149/mo and is dispensed from licensed 503A compounding pharmacies, allowing flexible dosing schedules tailored to your genetics and response. Unlike brand-name Ozempic, which comes in preset weekly doses, compounded therapy can be adjusted week-by-week based on your tolerance and results. Your dose may need to go up as you progress through treatment, but PlexusDx's flat pricing model means your monthly cost won't increase with dose adjustments.

PlexusDx also offers Oral Semaglutide (starting at $249/mo) and the Microdose GLP-1 Protocol ($129/mo flat) for patients who prefer non-injection options or need a gentler entry into therapy. All medications are HSA/FSA eligible, no membership is required, and PlexusDx serves all 50 states without insurance requirements.

What Increases Your Chances of Success With Semaglutide

Genetic predisposition matters: individuals with protective variants in GLP1R and lower-risk FTO alleles tend to respond more robustly to semaglutide and may reach therapeutic response at lower doses. Conversely, carriers of certain high-risk variants may require higher doses or combination therapy to achieve target weight loss. The PlexusDx Precision Peptide Genetic Test reveals these predispositions so your clinician can set realistic expectations and choose the optimal medication from day one.

Behavioral consistency amplifies medication effectiveness: patients who track food intake, maintain a calorie deficit of 500–750 kcal below maintenance, exercise at least 150 minutes weekly, prioritize sleep (7–9 hours nightly), and manage stress show weight loss rates 2–3 times higher than those who take medication alone. Semaglutide reduces hunger and improves satiety, but you must capitalize on that advantage through deliberate eating and lifestyle choices.

Early side-effect management and dose titration improve adherence and results: nausea, vomiting, and constipation are common in the first 4–8 weeks but typically resolve with slower dose escalation and dietary adjustments. Patients who start at lower doses and increase gradually experience fewer dropouts due to side effects and better sustained weight loss. PlexusDx's flexible compounded approach supports gradual titration, whereas fixed-dose pens may escalate too quickly for sensitive individuals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Does Ozempic guarantee weight loss for everyone?

No. While semaglutide produces weight loss in most patients (approximately 70–80% of trial participants), individual results vary from minimal loss to 30% body weight reduction. Genetic factors, lifestyle adherence, baseline metabolism, and medication tolerance all influence outcomes. PlexusDx uses genetic testing to predict your likely response category and personalize your therapy accordingly.

How much weight can you lose on semaglutide?

Clinical trials show average weight loss of 9.2–15.3% of baseline body weight over 68 weeks, with the highest-dose group (2.4 mg weekly) achieving the greatest loss. However, individual results range from 5% to 30% depending on genetics, adherence, and metabolic factors. PlexusDx Precision Peptide Genetic Test identifies your peptide-pathway profile to forecast your personalized weight loss range.

What is the cost of semaglutide therapy at PlexusDx?

PlexusDx Compounded Semaglutide Injection starts at $149/mo and Oral Semaglutide starts at $249/mo. There is no membership fee, and the medications are HSA/FSA eligible. Your dose may need to go up during treatment, but your price won't—PlexusDx maintains flat monthly pricing across all dose levels. The optional Precision Peptide Genetic Test is $99 and available after your first month of therapy.

Is compounded semaglutide as safe as brand-name Ozempic?

Yes, when dispensed from licensed 503A compounding pharmacies. PlexusDx sources all compounded medications from licensed 503A facilities that follow strict quality and sterility standards. Both compounded and brand-name semaglutide contain the same active ingredient and produce similar clinical outcomes, though compounded versions offer flexible dosing and lower cost.

Can genetic testing predict if semaglutide will work for me?

Yes. PlexusDx Precision Peptide Genetic Test analyzes variants in GLP1R, GIPR, FTO, and MC4R genes—plus 46 additional peptide variants across 14 metabolic pathways—to predict your semaglutide response strength and identify whether a dual-compound approach or alternative therapy may suit you better. This genetic insight, combined with your medical history and lifestyle factors, helps your clinician optimize therapy from the start.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves